Literature DB >> 21879891

Asthma phenotypes and interleukin-13--moving closer to personalized medicine.

Monica Kraft.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21879891      PMCID： PMC4390041          DOI： 10.1056/NEJMe1108666

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  Asthma.

Authors:  W W Busse; R F Lemanske
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

2.  Significant variability in response to inhaled corticosteroids for persistent asthma.

Authors:  Stanley J Szefler; Richard J Martin; Tonya Sharp King; Homer A Boushey; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Myrna Dolovich; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Elizabeth Mauger; Stephen P Peters; Christine A Sorkness
Journal:  J Allergy Clin Immunol       Date:  2002-03       Impact factor: 10.793

3.  T-helper type 2-driven inflammation defines major subphenotypes of asthma.

Authors:  Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

4.  Lebrikizumab treatment in adults with asthma.

Authors:  Jonathan Corren; Robert F Lemanske; Nicola A Hanania; Phillip E Korenblat; Merdad V Parsey; Joseph R Arron; Jeffrey M Harris; Heleen Scheerens; Lawren C Wu; Zheng Su; Sofia Mosesova; Mark D Eisner; Sean P Bohen; John G Matthews
Journal:  N Engl J Med       Date:  2011-08-03       Impact factor: 91.245

5.  Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Authors:  M Humbert; R Beasley; J Ayres; R Slavin; J Hébert; J Bousquet; K-M Beeh; S Ramos; G W Canonica; S Hedgecock; H Fox; M Blogg; K Surrey
Journal:  Allergy       Date:  2005-03       Impact factor: 13.146

6.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.

Authors:  Z Zhu; R J Homer; Z Wang; Q Chen; G P Geba; J Wang; Y Zhang; J A Elias
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

7.  Airway fibroblasts in asthma manifest an invasive phenotype.

Authors:  Jennifer L Ingram; Molly J Huggins; Tony D Church; Yuejuan Li; Dave C Francisco; Simone Degan; Rafael Firszt; Denise M Beaver; Njira L Lugogo; Ying Wang; Mary E Sunday; Paul W Noble; Monica Kraft
Journal:  Am J Respir Crit Care Med       Date:  2011-03-25       Impact factor: 21.405

8.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.

Authors:  Eric D Bateman; Homer A Boushey; Jean Bousquet; William W Busse; Tim J H Clark; Romain A Pauwels; Søren E Pedersen
Journal:  Am J Respir Crit Care Med       Date:  2004-07-15       Impact factor: 21.405

9.  Requirement for IL-13 independently of IL-4 in experimental asthma.

Authors:  G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

10.  Increased sputum and bronchial biopsy IL-13 expression in severe asthma.

Authors:  Shironjit K Saha; Mike A Berry; Deborah Parker; Salman Siddiqui; Angela Morgan; Richard May; Phillip Monk; Peter Bradding; Andrew J Wardlaw; Ian D Pavord; Christopher E Brightling
Journal:  J Allergy Clin Immunol       Date:  2008-03       Impact factor: 10.793
  10 in total
  15 in total

Review 1.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Authors:  Thomas A Wynn; Thirumalai R Ramalingam
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 2.  Periostin function in communication with extracellular matrices.

Authors:  Akira Kudo; Isao Kii
Journal:  J Cell Commun Signal       Date:  2017-10-30       Impact factor: 5.782

Review 3.  Targeted therapies for systemic sclerosis.

Authors:  Christopher P Denton; Voon H Ong
Journal:  Nat Rev Rheumatol       Date:  2013-04-09       Impact factor: 20.543

4.  TGF-β-mediated airway tolerance to allergens induced by peptide-based immunomodulatory mucosal vaccination.

Authors:  H Michael; Y Li; Y Wang; D Xue; J Shan; B D Mazer; C T McCusker
Journal:  Mucosal Immunol       Date:  2015-03-18       Impact factor: 7.313

5.  IL-13 Augments Compressive Stress-Induced Tissue Factor Expression in Human Airway Epithelial Cells.

Authors:  Jennifer A Mitchel; Silvio Antoniak; Joo-Hyeon Lee; Sae-Hoon Kim; Maureen McGill; David I Kasahara; Scott H Randell; Elliot Israel; Stephanie A Shore; Nigel Mackman; Jin-Ah Park
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

Review 6.  Reinventing polysomnography in the age of precision medicine.

Authors:  Diane C Lim; Diego R Mazzotti; Kate Sutherland; Jesse W Mindel; Jinyoung Kim; Peter A Cistulli; Ulysses J Magalang; Allan I Pack; Philip de Chazal; Thomas Penzel
Journal:  Sleep Med Rev       Date:  2020-03-20       Impact factor: 11.609

Review 7.  Linking GATA-3 and interleukin-13: implications in asthma.

Authors:  Sheikh Rayees; Fayaz Malik; Syed Imran Bukhari; Gurdarshan Singh
Journal:  Inflamm Res       Date:  2013-12-22       Impact factor: 4.575

8.  Point-of-Care Technologies for the Advancement of Precision Medicine in Heart, Lung, Blood, and Sleep Disorders.

Authors:  Mary Emma Gorham Bigelow; Brian G Jamieson; Chi On Chui; Yufei Mao; Kyeong-Sik Shin; Tony Jun Huang; Po-Hsun Huang; Liqiang Ren; Bishow Adhikari; Jue Chen; Erin Iturriaga
Journal:  IEEE J Transl Eng Health Med       Date:  2016-07-22       Impact factor: 3.316

Review 9.  Newer treatments in the management of pediatric asthma.

Authors:  Paul D Robinson; Peter Van Asperen
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

10.  IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis.

Authors:  Emily Hams; Michelle E Armstrong; Jillian L Barlow; Sean P Saunders; Christian Schwartz; Gordon Cooke; Ruairi J Fahy; Thomas B Crotty; Nikhil Hirani; Robin J Flynn; David Voehringer; Andrew N J McKenzie; Seamas C Donnelly; Padraic G Fallon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.